- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Authors
Latest:
Addressing Social Determinants of Health Through Value-Based Oncology Care: Yale Podnos, MD, MPH, FACSYale Podnos, MD, MPH, FACS, discusses strategies to address social determinants of health in oncology, improve clinical trial enrollment for underserved communities, and leverage value-based care models to reduce financial toxicity and ensure equitable cancer care.
Latest:
Contributor: For Better or Worse, Inflation Isn’t New to Health InsurersIn this column, a health insurance executive discusses 2 ways to address rising inflation, including moving past the traditional fee-for-service payment model.
Latest:
Neoadjuvant KN026 Plus Docetaxel Demonstrate Early Activity in HER2+ Breast CancerA combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.
Latest:
Pharmacist-Led Review of Empagliflozin and Ertugliflozin Following Formulary UpdateManagement of empagliflozin and ertugliflozin may be suboptimal following an insurance carrier’s formulary updates. Pharmacists may improve the management.
Latest:
Navigation and Clinician Payment Investments Enhance Colorectal Cancer Screening BenefitsInvesting in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.
Latest:
Predicting Hospital Readmission in Medicaid Patients With Diabetes Using Administrative and Claims DataA statistical model based entirely on claims data can accurately predict 30-day hospital readmission in Medicaid patients with diabetes.
Latest:
Hospital Strategies in Commercial Episode-Based ReimbursementThis study reports qualitative findings from an explanatory sequential mixed-methods investigation to understand hospitals’ approaches to a novel commercial episode-based reimbursement incentive program.
Latest:
Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment DurationA nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.
Latest:
The Role of Advanced Technologies in Improving Diabetes OutcomesThis article reviews underlying barriers to health care access and discusses how a value-based diabetes care model could improve patient outcomes and reduce long-term costs.
Latest:
COVID-19 Control in the United States: The Case for MaskingIn the control of COVID-19, the future perfect of the vaccine should not be the enemy of the present good, which is masking.
Latest:
How In Vivo CAR T-Cell Therapies Could Rewrite the Cancer Care PlaybookIn vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.
Latest:
Identifying Complex Patients Using Adjusted Clinical Groups Risk Stratification ToolIn this study, the authors developed a method for use in primary care to identify a group of patients with complex care needs using Aggregated Diagnosis Groups.
Latest:
ASRS 2023: Intended vs Actual Treatment Intervals Between Intravitreal Anti-VEGF Injections: Effects of Treatment DaysIn the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.
Latest:
Health Outcomes Under Full-Risk Medicare Advantage vs Traditional MedicarePhysician groups under 2-sided risk–based Medicare Advantage provide care associated with higher quality and efficiency compared with care by these same groups under fee-for-service Medicare.
Latest:
A Case-Control Study of Length of Stay OutliersLength of stay outliers are associated with hospital-acquired infections, complications, and discharge to facility, as opposed to nonmodifiable risk factors like age and comorbidities.
Latest:
Social Determinants of Health Score: Does It Help Identify Those at Higher Cardiovascular Risk?Calculating a social score is feasible and it predicts cardiovascular outcomes. In order to do this, institutions have to collect social determinants of health.
Latest:
Factors Associated With Unplanned Admissions Among Patients With Chronic ConditionsThis study identified risk factors for unplanned admissions among patients with multiple chronic conditions to inform focused interventions.
Latest:
Management of Procalcitonin Test Overuse in an Emergency Department Through a Computer AlgorithmProcalcitonin test demand from the emergency department is growing, necessitating the implementation of strategies to address overuse. Successful interventions must be based on information technology.
Latest:
Screening for Health Literacy, Social Determinants, and Discrimination in Health PlansThis study provides insight on the experiences of patients of a national health plan with 2 structural determinants of health—health care discrimination and health literacy—and how those interact with social determinants of health and patient demographics.
Latest:
Predicting Drug-Drug and Drug-Gene Interactions in a Community Pharmacy PopulationThe probability of drug interactions increases when genetic polymorphisms are considered, indicating that pharmacogenetic assessment may be useful in predicting the presence and severity of interactions.
Latest:
Changes in Electronic Notification Volume and Primary Care Provider BurnoutPrimary care provider burnout was analyzed before and after a national initiative to optimize the electronic health record inbox notification system at the Veterans Health Administration.
Latest:
Real-World Digitally Based Diabetes Management Program Implementation by a Large EmployerThis study offers new insights to self-insured employers and health plans related to investment in digitally based disease management programs and enrollee engagement.
Latest:
Projected US Savings From Biosimilars, 2021-2025Projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry. Savings were $124.5 billion under an upper-bound scenario.
Latest:
Geographic Variations and Facility Determinants of Acute Care Utilization and Spending for ACSCsEmergency department (ED) visits and hospitalizations for ambulatory care–sensitive conditions (ACSCs) among Medicaid patients constitute almost 40% of all ED visits and hospitalizations, with lower rates observed in areas with greater proximity to urgent care facilities and density of rural health clinics.
